Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Elias Jabbour; Van Morris; Hagop Kantarjian; Cameron C. Yin; Elizabeth Burton; Jorge Cortes

doi:10.1182/blood-2012-04-424192

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Elias Jabbour, Van Morris, Hagop Kantarjian, Cameron C. Yin, Elizabeth Burton, Jorge Cortes

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	3382-3383
Number of pages	2
Journal	Blood
Volume	120
Issue number	16
DOIs	https://doi.org/10.1182/blood-2012-04-424192
State	Published - Oct 18 2012
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2012-04-424192

Cite this

@article{36666f14260244f6ba12170c438fc509,

title = "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors",

author = "Elias Jabbour and Van Morris and Hagop Kantarjian and Yin, {Cameron C.} and Elizabeth Burton and Jorge Cortes",

year = "2012",

month = oct,

day = "18",

doi = "10.1182/blood-2012-04-424192",

language = "English (US)",

volume = "120",

pages = "3382--3383",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "16",

}

TY - JOUR

T1 - Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

AU - Jabbour, Elias

AU - Morris, Van

AU - Kantarjian, Hagop

AU - Yin, Cameron C.

AU - Burton, Elizabeth

AU - Cortes, Jorge

PY - 2012/10/18

Y1 - 2012/10/18

UR - http://www.scopus.com/inward/record.url?scp=84868091978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868091978&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-04-424192

DO - 10.1182/blood-2012-04-424192

M3 - Letter

C2 - 23086624

AN - SCOPUS:84868091978

SN - 0006-4971

VL - 120

SP - 3382

EP - 3383

JO - Blood

JF - Blood

IS - 16

ER -

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this